Nautilus Biotechnology (NAUT) Cash from Operations Growth (1y) (2021 - 2026)
Nautilus Biotechnology (NAUT) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 158.60% |
| 10 | Nautilus Biotechnology | 214.01 Mn | 118.14 Mn | - | 6.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.01% |
| Dec 31, 2025 | 13.52% |
| Sep 30, 2025 | 15.85% |
| Jun 30, 2025 | 13.63% |
| Mar 31, 2025 | 14.32% |
| Dec 31, 2024 | -2.94% |
| Sep 30, 2024 | -11.71% |
| Jun 30, 2024 | -14.08% |
| Mar 31, 2024 | -29.88% |
| Dec 31, 2023 | -33.95% |
| Sep 30, 2023 | -22.72% |
| Jun 30, 2023 | -0.15% |
| Mar 31, 2023 | -1.53% |
| Dec 31, 2022 | 1.35% |
| Sep 30, 2022 | 32.53% |
| Jun 30, 2022 | -63.16% |
| Mar 31, 2022 | -97.27% |
| Dec 31, 2021 | -1,814.04% |
| Sep 30, 2021 | -2,819.19% |